Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N5F7
UPID:
NKAP_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N5F7; Q6IPW6; Q96BQ2; Q9H638
Background:
The NF-kappa-B-activating protein plays a pivotal role in various cellular processes, including acting as a transcriptional repressor and corepressor in Notch-mediated signaling crucial for T-cell development. It is also involved in NF-kappa-B activation, a key pathway in inflammation and immune responses, through its association with chromatin at specific promoters.
Therapeutic significance:
Linked to Intellectual developmental disorder, X-linked, syndromic, Hackman-Di Donato type, the NF-kappa-B-activating protein's genetic variants highlight its clinical relevance. Understanding its role could pave the way for innovative therapeutic strategies targeting this protein to manage or treat the associated disorder.